Stock Taper 
NGEN
$2.05
▼ DOWN 9.69% (-0.22)
KEY STATISTICS
Market Cap$168.50 M
52w High$6.30
52w Low$1.58
Dividend Yield—
Frequency—
P/E-5.01
Volume607.39K
Shares Out.82.19M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Adam H. Rogers
ABOUT
SECTOR
Healthcare
WENT PUBLIC
February 8, 2021
METHOD OF GOING PUBLIC
Dual Listing
FULL TIME EMPLOYEES
8
PRICE TARGET
Target High$12.00
Target Low$12.00
Target Median$12.00
Target Consensus$12.00
UPCOMING EARNINGS
DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU
PRICE
$2.05 ▼ DOWN 9.69% (−$0.22)About NervGen Pharma Corp. Common stock
https://www.nervgen.com ↗NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.
INDUSTRY
Biotechnology
A PRODUCT NERVGEN PHARMA CORP. COMMON STOCK IS KNOWN FOR
NVG-291
NVG-291 is NervGen's lead neuroreparative peptide in clinical trials, designed to promote nervous system repair after injury or disease, primarily targeting spinal cord injury.
ETFS HOLDING THIS STOCK
ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
1.15%
HOLDERS
29
TOP 12 OF 29 · RANKED BY POSITION SIZE
Bank Of America Corp /De/
Marshall Wace, Llp
Royal Bank Of Canada
Integrated Wealth Concepts LLC
Bank Of Montreal /Can/
Captrust Financial Advisors
Advisor Group Holdings, Inc.
Cetera Investment Advisers
Traynor Capital Management, Inc.
Td Waterhouse Canada Inc.
Liberty Wealth Management LLC
Hrt Financial LP
RATINGS SNAPSHOT
Overall rating: C-
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
